Mechanism of ischaemia reperfusion injury
Myocardial infarction is usually caused by rupture of an atheromatous plaque in a coronary artery. Re-establishment of coronary blood flow (reperfusion) is mandatory to salvage the ischaemic myocardium but this is accompanied by dramatic changes in mitochondrial permeability transition pore (mPTP) opening, generation of reactive oxygen species (ROS), bioavailability of nitric oxide (NO), intracellular distribution of Ca 2+ and Na + , and pH. Paradoxically, reperfusion itself can actually cause cardiomyocyte death and subsequent irreversible myocardial injury, a phenomenon termed 'ischaemia reperfusion injury (IRI)'. 9 ( Fig. 1 ).
Mitochondrial dysfunction during myocardial ischaemia reperfusion
In order to meet the high energy demand for both contractility and diastolic relaxation, the heart needs a continuous energy supply, which depends on the synthesis of adenosine triphosphate (ATP). Approximately 95% of this ATP comes from mitochondrial oxidative phosphorylation. 10 Thus, mitochondrial function has been considered as a key factor in the aetiology of myocardial ischaemia, a state of energy deficit in the heart. Mitochondrial dysfunction affects cell viability through a wide array of events including reduction or loss of ATP synthesis, increase in ATP hydrolysis, 11 impairment in ionic homeostasis, 12 and formation of ROS. 13 All these suggest a critical role of mitochondria in myocardial IRI and, as such, mitochondria may act as critical triggers, mediators and effectors for protective strategies directed against myocardial IRI. Under physiological conditions, the mitochondrial inner membrane is impermeable (except for a few selected metabolites and ions). However, under pathological conditions such as myocardial ischaemia, oxygen and nutrient deprivation causes a non-selective opening of the inner mPTP, resulting in depolarization and uncoupling/impairment of oxidative phosphorylation. 14 This not only leads to ATP depletion but also causes the breakdown of any available ATP, which subsequently induces the hydrolysis of ATP and the enhancement of mitochondrial inorganic phosphate. 12 On the other hand, during ischaemia (in the absence of oxygen) cellular metabolism switches to anaerobic glycolysis and the subsequent accumulation of lactate reduces intracellular pH (lower than 7.0). 15 Depletion of ATP and acidosis impede the ability of the Na + /K + antiporter to remove excess Na + caused by the increase of intracellular proton accumulation-induced activation of Na + /H + ion exchanger, resulting in intracellular Ca 2+ overload and mitochondrial swelling. 11 Influx of Ca 2+ into the mitochondria and an increase in ROS production both favour mPTP opening, but the associated acidosis obstructs its opening. After reperfusion, a quick pH correction exacerbates the opening of the mPTP within a few min. 16 17 This, in turn, leads to an abrupt increase in flow of accumulated electrons and an associated increase in electron leak which, together with the damaged electron transport chain, not only damages mitochondria but also promotes a burst production of superoxide anion and other ROS, 18 19 eventually causing cell death ( Fig. 1) . Therefore, preventing mPTP opening at the time of reperfusion (mPTP remains closed during ischaemia) or timely removal of damaged mitochondria would serve as promising therapeutic avenues to protect the heart from myocardial IRI. It has been shown that direct inhibition of mPTP opening by cyclosporine A, attenuated myocardial injury after reperfusion both in experimental studies in small 20 and large animals 21 and in patients with acute ST-elevation myocardial infarction. 22 Treatments targeting inhibition of mPTP have been proved to be cardioprotective and are currently being evaluated for clinical use. 23 24 As such, the mPTP provides an important therapeutic target for preventing lethal myocardial IRI. However, because of the complexity of mitochondrial metabolism and the fact that most experimental studies have been performed on isolated mitochondria which lack cellular context, further investigation transition pore (mPTP) opening which elevates reactive oxygen species (ROS) generation, decreases nitric oxide (NO) bioavailability, and disrupts intracellular distribution of Ca 2+ , Na + and pH, resulting in cardiomyocyte death and subsequent irreversible myocardial injury. is needed to reveal the whole picture of the role and mechanisms of mPTP in myocardial IRI and its application as a therapeutic target for cardioprotection.
Overproduction of reactive oxygen species during myocardial ischaemia reperfusion ROS such as superoxide anion, hydrogen peroxide, and hydroxyl radicals are generated as by-products of cellular metabolism. Under physiological conditions, small amounts of ROS are beneficial as they participate in normal cellular signaling 18 and serve as an important mediator in the cardioprotection of IPC. 25 However, under stress such as myocardial ischaemia reperfusion, after prolonged ischaemia, re-introduction of blood flow (reperfusion) leads to a massive burst of ROS production from damaged mitochondria. 11 This exceeds the defensive capacity of the cells (e.g. catalase,
glutathione peroxidase, and superoxide dismutase) and is detrimental to cardiomyocytes. Production of large quantities of ROS results in overloading of Ca 2+ , 2 10 breakdown of critical proteins as a result of protein oxidation, 26 generation of peroxynitrite (ONOO-), 27 disruption of cholesterol containing membranes as a result of lipid peroxidation, 28 opening of the mPTP, 29 and reduction of nitric oxide availability. 30 This phenomenon is termed oxidative stress and ultimately causes cell death. As increased generation of ROS during the first min of reperfusion is a major contributor to the pathogenic mechanisms underlying myocardial IRI, antioxidant therapy has been considered an appropriate option of preventive treatment. However, results from experimental and clinical studies are inconsistent. We and others have shown that antioxidant treatment with N-acetylcysteine and/or allopurinol, attenuates post-ischaemic myocardial injury in a rat model of myocardial IRI 27 31 and in patients undergoing coronary artery bypass surgery. 32 However, others did not observe a beneficial antioxidant effect in patients with vascular disease, 33 34 and long-term antioxidant (vitamin E) supplementation does not prevent major cardiovascular events and may even increase the risk of heart failure. 35 A possible explanation for this contradiction may be the difference in timing and the choice of an antioxidant that targets specific ROS. It may also be because of the inability of the antioxidant to actually enter the cell. 36 Given that mitochondria are considered as the primary site of ROS generation, discovery of mitochondrial-specific antioxidants 37 38 may provide more effective therapy in combating myocardial IRI.
Reduction of nitric oxide bioavailable during myocardial ischaemia reperfusion
Nitric oxide (NO) is produced by NO synthases [NOS, with three isoforms respectively called endothelial (eNOS), neuronal (nNOS), and inducible NOS (iNOS)] through converting L-arginine to L-citruline in the presence of oxygen. NO is a critical signalling molecule in the cardiovascular system, acting as one of the most important defence mechanisms against myocardial IRI and as a mediator of cardioprotective interventions such as IPC and IPo. NO exerts its cardioprotective effect via distinct mechanisms: (1) activation of NO-sensitive guanylyl cyclase, 39 (2) inhibition of mitochondrial Ca 2+ influx 40 41 and activation of the mitochondrial K ATP channel, 42 (3) activation of cGMP, 43 (4) enhancement of cyclooxygenase-2, 44 and (5) abrogation of ONOO-mediated lipid radical chain propagation. 45 In the setting of prolonged myocardial ischaemia, the activity/activation of NOS ( primarily eNOS and nNOS) is reduced concomitant with the reduced supply of oxygen that is required for the synthesis of NO from NOS. Thus, deprivation of oxygen during ischaemia leads to reduced or diminished NO release. Hence, enhancement of NOS activity/activation and NO bioavailability has been shown to be cardioprotective. Indeed, eNOS knockout exacerbates post-ischaemic myocardial injury in mice subjected to myocardial IRI, 46 while overexpression of eNOS improves post-ischaemia cardiac functional recovery. 47 Also, enhancing NO bioavailability by exogenous application of NOS and L-arginine, attenuates ischaemia reperfusion-induced microcirculatory alterations 48 and post-ischaemic infarction. 49 However, high concentration of NO in the presence of increased superoxide anion production may be detrimental as a consequence of increased formation of peroxynitrite (ONOO-), which exacerbates post-ischaemic myocardial injury. Interestingly, treatment with a NO donor in combination with an antioxidant, has been shown to reduce post-ischaemic myocardial infarct size and improve contractile function in the isolated rat heart model, 49 indicating that maintaining a physiological concentration of NO is important for NO to confer its cardioprotective effects. Taken together, the cardioprotective effects of NO depend on its concentration/production, subcellular localization, and its bioavailability. Thus, further studies are needed to better understand the metabolism and dynamics of NO during myocardial IRI, in order to liberate the correct amount of NO in the correct place and at the correct time, under varying pathological conditions.
Other mechanisms of pre-and post-conditioning cardioprotection
Many of the endogenous signalling pathways that participate in anaesthetic-mediated cardioprotection have been identified. Mitochondrial oxidative phosphorylation is the main source of ATP production in the heart, providing the steady supply of ATP required to sustain cardiac contraction, and, as such, mitochondria have been the main focus in cardioprotection. Indeed, signalling pathways targeting cell factions other than mitochondria, such as the nucleus and membrane, also play important roles. For instance, sevoflurane postconditioning by activating Nrf2, upregulated antioxidant genes in the nucleus, resulting in attenuation of myocardial ischaemia reperfusion injury. 50 The integrity and functionality of the cell membrane has also been proposed 51 to mediate the cardioprotection of anaesthetics such as sevoflurane 52 and isoflurane. 53 Sevoflurane preconditioning has also been shown to confer delayed cardioprotection via inhibiting Beclin 1-mediated autophagic cell death, in cardiac myocytes subjected to hypoxia/reoxygenation injury after brief exposure to sevoflurane 24 h before inducing hypoxia, 54 and is likely to involve both mitochondrial and nonmitochondrial mechanisms. Further in-depth investigation is needed to decipher their relative importance, timing of activation, and interactions, and to provide more insight into the mechanisms of volatile anaesthetic cardioprotection.
Protection against myocardial ischaemia reperfusion injury

Ischaemic conditioning
Ischaemic conditioning is achieved by intermittent occlusion of a coronary vessel either locally or remotely, by inducing reversible ischaemia of a distant organ (remote ischaemic conditioning), and limits myocardial infarct size. Ischaemic conditioning can be applied at different time points: before the induction of a period of prolonged ischaemia (IPC, ischaemic preconditioning) or immediately at the onset of reperfusion after prolonged ischaemia (IPo, ischaemic postconditioning). All these cardioprotective ii46 | Xia et al.
strategies confer their effects by activating endogenous pro-survival signalling pathways.
Ischaemic preconditioning
Ischaemic preconditioning (IPC) was first described by Murry and co-workers in a dog model. 55 The first clinical evidence was provided by inducing several cycles of transient non-lethal ischaemia, using an aortic cross-clamp interspersed with reperfusion. This reduced post-ischaemic myocardial troponin T release and ATP depletion in patients undergoing cardiac bypass surgery. 56 The protective effect of IPC is biphasic. The 'first window' or early phase arises immediately after ischaemic stress and lasts for two to three h. The 'second window' or late phase cardioprotection occurs 12-24 h after initial preconditioning and lasts for up to 48-72 h. [57] [58] [59] Ischaemic preconditioning confers its early phase protection through the modification of existing prosurvival proteins in the heart, to protect against myocardial infarction, but it has no significant effect on limiting the degree of contractile dysfunction. The late phase of ischaemic preconditioning protection, is a result of the production of cytoprotective proteins in the myocardium and protects the heart from cardiomyocyte death while improving post-ischaemic cardiac functional recovery. 57 Thus, the late phase of IPC cardioprotection is more clinically applicable for its more significant protection and longer duration. IPC confers cardioprotection by creating a cardiac 'memory' between the triggers and end-effectors in the signalling pathways in order to keep the heart in a 'preconditioned' state. 60 Three major endogenous triggers of IPC are adenosine, 61 bradykinin, 62 and opioids, 63 all of them are classified as G coupled protein receptor dependent triggers. There are others including ROS, the mitochondrial K ATP channel and NO, which probably trigger IPC through the activation of G coupled proteins 64 and protein kinases. 65 After being stimulated by IPC, these triggers activate their downstream mediators, among which are mainly protein kinases, such as protein kinase C (PKC), Akt, tyrosine kinase, and the mitogen activated protein kinase (MAPK). PKC was one of the first mediators of IPC to be identified. 66 67 Gene knockout of PKC-ε cancels the cardioprotective effects of IPC in mice. 68 However, in isolated ischaemic reperfused rat hearts, PKC-δ inhibition attenuates myocardial IRI, while PKC-ε activator (but not PKC-δ activator) mimics IPC, 69 supporting the notion that PKC activation-mediated cardioprotection in IPC is isoform-specific. Further investigation is needed to provide a full picture of the beneficial or detrimental role of specific isoforms of PKC activation in the process of IPC. Numerous upstream activators (e.g. PI3K-Akt, 70 NO, 71 ) of PKC have also been suggested as IPC mediators. There are others that work in parallel with the PKC pathway in IPC, including receptor tyrosine kinase, MEK1/2-Erk1/2, the Jak-STAT pathways, GSK-3β, and ROS 25 76 (Fig. 2 ).
The ultimate end-effector of IPC has not been determined, despite extensive research. The mitochondrion is where most signalling pathways governing IPC cardioprotection converge. The opening of the mitochondrial K ATP channel by IPC inhibits mitochondrial Ca 2+ overload 77 78 and attenuates myocardial IRI.
Other studies have shown that opening of the mitochondrial K ATP channel facilitates the generation of small amounts of ROS and activates PKC, which in turn phosphorylates the mitochondrial K ATP channel and keeps it in the opened state. 79 Inhibition of mPTP opening has also been considered as the final step in the process of IPC. It has been shown that IPC may inhibit mPTP opening through GSK-3β, eNOS, or via the reperfusion injury salvage kinase (RISK) pathway 80 81 (Fig. 2 ). Of note, there are also other components that have been suggested as the end-effectors of IPC, for instance, the cytoskeleton, gap-junctions, and the Na + /H + exchanger. 80 Although IPC has been reported to be effective in both experimental and clinical studies, it needs to be performed before the onset of prolonged myocardial ischaemia [i.e. acute myocardial infarction (AMI)], which is neither predictable nor feasible in most clinical situations. Therefore, the majority of clinical investigations of IPC have been restricted to various cardiovascular surgical procedures, including both vascular and cardiac operations in which the ischaemia is predictable.
Ischaemic postconditioning
Recently, effort has focused on modifying events occurring at the time of myocardial reperfusion (ischaemic postconditioning, IPo). Applying transient brief interruptions of reperfusion by ischaemic episodes to reduce myocardial injury, has higher clinical potential than IPC as, for example, it can be performed after myocardial infarction. IPo was first demonstrated by Zhao and his coworkers, in a rabbit model in which the investigators showed that three repeated cycles of 30 s reperfusion followed by 30 s of occlusion, after a prior 60 min of coronary occlusion, markedly reduced post-ischaemic myocardial infarct size and improved cardiac functional recovery. 82 IPo has also shown considerable promise in clinical settings. In children undergoing corrective surgery for tetralogy of fallot, IPo, achieved by two cycles of unclamping the aorta for 30 s and then re-clamping the aorta for 30 s, reduced the concentrations of CK-MB and troponin T (two reliable markers of myocardial injury) 2 h after surgery. 83 This has also been confirmed in a number of clinical studies including cardiac surgery for congenital heart disease, 84 aortic valve replacement, 85 and percutaneous coronary intervention. 86 It is now widely accepted that IPo confers its cardioprotective effects via two intracellular pathways, the RISK pathway which involves PI3K/Akt 87 and the survival activating factor enhancement pathway (SAFE), which involves Jak/STAT3. 88 These pathways converge in the mitochondrion which is, obviously, an integration point that is decisive for cardiomyocyte survival. 14 As the experimental design of IPo mimics IPC and their cardioprotective effects are similar, it is not surprising that IPo and IPC share related cardioprotective signalling pathways. Indeed, elements of the RISK pathway, including PI3K, Akt, eNOS, and adenosine receptors have also been shown to be involved in IPo (Fig. 3) . In isolated rat hearts, IPo stimulation reduced post-ischaemic infarct size with associated elevations in Akt, eNOS, and p70S6K, while these beneficial effects of IPo were abolished by PI3K inhibition (either by LY294002 or wortmannin), indicating the involvement of PI3K-Akt in IPo. 89 In addition, pharmacological inhibition of MEK1/2 abrogated IPo cardioprotection. 90 Furthermore, other components of the RISK pathway, such as PKC, Protein G, and p38 MAPK, are implicated in IPo cardioprotection. 91 All these not only support the concept that cardioprotection of IPo shares a similar pathway (RISK) with IPC, but also suggest that the RISK pathway could be a common pathway mediating cardioprotection. However, the involvement of the RISK pathway in IPo has also been questioned. It was reported that Erk1/2 but not PI3K-Akt was involved in IPo cardioprotection in isolated rabbit hearts. 92 Similarly, in in vivo porcine hearts, IPo significantly increased Akt and Erk1/2 phosphorylation but failed to reduce post-ischaemic infarct size. 93 The reason for these controversial results is not clear, but a possible explanation would be the difference of the models and the protocols used in each experiment. However, this may also suggest that IPo may confer cardioprotective effects through RISK-independent pathways. Indeed, the more recently identified SAFE pathway has been shown to be essential and can be activated independent of the RISK pathway during IPo. 88 The SAFE pathway is initiated by moderate elevation of tumour necrosis factor (TNF)-α (a pro-inflammatory cytokine). The cardioprotective effects of IPo were lost in TNF-α knockout mice 94 and exogenous TNF-α given at the onset of reperfusion at a relative low dose can mimic the protective effects of IPo, 94 indicating that low doses of TNF-α might serve as a trigger of IPo cardioprotection. Interestingly, administration of TNF-α to mimic the protective effects of IPo did not lead to the activation of Akt or Erk1/2, 95 while inhibition of Erk1/2 (by PD98059) or PI3K (by wortmannin) aborted the protective effects mediated by TNF-α when applied at moderate dosage. 94 These findings together with the fact that Akt and Erk1/2 are components of the RISK pathway, provide evidence that downstream signalling of the SAFE pathway is different from that of RISK and that the SAFE pathway can be activated independently in the setting of IPo. This concept has been further supported by a study showing that neither Akt nor Erk1/ 2 inhibition had significant impact on IPo-induced reduction of post-ischaemic infarct size in an in vivo pig myocardial IRI model. 88 After initiation by IPo, TNF-α binds to its receptor (TNFR2 in myocardial IRI) and subsequently activates/phosphorylates signal transducer and activator of transcription 3 (STAT3), a transcription factor that has been shown to be an essential component of the SAFE pathway in IPo. Once phosphorylated/activated, tyrosinephosphorylated STAT3 shuttles into the nucleus and initiates stress-responsive gene transcription, 96 97 serine-phosphorylated STAT3 moves to mitochondria to regulate the mitochondrial respiratory chain 97 98 (Fig. 3) . The importance of STAT3 activation in the context of IPo has been demonstrated by both pharmacological inhibition 99 and genetic deletion of STAT3. 100 However, information regarding how IPo activates STAT3 is lacking. Moreover, although STAT3 is recognized as a transcription factor, its activation during myocardial IRI is much too rapid to assume that it works by modulating gene transcription. Of note, it has been shown that the RISK pathway is involved (but not essential) in IPo cardioprotection and cross-talk exists between the RISK and SAFE pathways. 94 As Akt cannot be phosphorylated in STAT3 knockout mice subjected to IPC, 101 it suggests that IPo may activate Akt via STAT3. IPo also activates STAT3 and increases its mitochondrial expression which subsequently improves mitochondrial function in pig hearts. 99 Given that mitochondrial STAT3 co-localises with cyclophilin D, the target of the mPTP inhibitor, 102 and that mPTP also works as the end-effector of the RISK pathway, it follows that the SAFE and RISK pathways may converge at the mitochondria.
Remote ischaemic conditioning
Remote conditioning is a strategy whereby application of one or more cycles of non-lethal ischaemia reperfusion to an organ or tissue, distant from the heart either before inducing prolonged ischaemia (remote ischaemic preconditioning, RIPC), 103 or at the onset of reperfusion (remote ischaemic postconditioning) 104 protects against myocardial IRI. It was first discovered in 1997 when it was shown that repeated occlusions to a lower limb of rabbits could attenuate myocardial infarct size after myocardial IRI, and it was initially called 'ischaemic preconditioning at a distance'. 105 This simple and effective technique has subsequently been translated into clinical use. The first clinical application of RIPC in humans was in 2006 in children undergoing cardiac surgery, where RIPC (four 5 min cycles of lower limb ischaemia and reperfusion using a blood pressure cuff ) significantly reduced postoperative troponin I release and inotrope requirement. 106 However, negative results have also been reported in cardiac bypass surgery. 107 108 The possible explanation for this contradiction is not clear but may be as a result of: (1) the use of anaesthetics such as sevoflurane, opioids and propofol, which can exert cardioprotective effects themselves during cardiac bypass surgery; (2) differences in protocol and the timing of RIPC application; and (3) differences in patient population and type of cardiac surgery. Thus, large multi-centre, randomized, controlled clinical trials are needed to confirm the cardioprotective effects of RIPC. Indeed, a recent large-scale trial has shown that RIPC is cardioprotective in patients undergoing elective CABG under ischaemic cardioplegic arrest, in which medication with β-blockers, statins, angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) was not interrupted for the CABG, 109 while the use of propofol was discontinued and diabetes was an exclusion criterion. 110 The efficacy of RIPC mediated cardioprotection was reflected in a reduction in serum troponin release, assessed by the area under the curve values for serum troponin I from baseline to 72 h after surgery. Aortic cross-clamp time was the major independent variable that impacted efficacy of RIPC. 109 However, two recent large-scale, prospective, randomized, sham-controlled trials of RIPC in cardiac surgery with cardiopulmonary bypass, have shown that RIPC was not effective when utilized in anaesthetised patients immediately before surgery. 111 112 This may be related to the use of propofol, which induces cardioprotection via different mitochondrially related molecular mechanisms. 113 In contrast, RIPC applied some time before surgery, increases myocardial salvage-index in patients with acute myocardial infarction. 114 Experimentally, we and others have demonstrated that RIPC repeated for three consecutive days, reduced myocardial infarction in rats with chronic heart failure after myocardial infarction 115 and in rats with diabetes, 116 117 two main cofounders that impact the efficacy of RIPC cardioprotection. These suggest that RIPC initiated at a remote time may allow the second-window of cardioprotection to develop and, thereby, improve tolerance to ischaemia during cardiac surgery. Thus, RIPC should not be abandoned but merits further clinical trials concerning optimal timing of application. Although RIPC currently has been extensively investigated, the underlying mechanism remains unclear. Three inter-related 
Cardioprotection by anaesthetics
Application of certain drugs used in anaesthesia (e.g. isoflurane, sevoflurane, propofol, and opioids) before or during the early phase of reperfusion can also reduce myocardial ischaemia reperfusion injury, a phenomenon that is termed anaesthetic preconditioning (APreC) and postconditioning (APoC), or collectively referred to as anaesthetic pre-or post-conditioning (APC).
Mechanisms of APoC cardioprotection conferred by volatile anaesthetics, propofol or opioids
Similar to ischaemic preconditioning, volatile anaesthetics and opioids provide protection against myocardial IRI by stimulating the generation of a small amount of ROS, which triggers and enhances the production of endogenous antioxidant enzymes and activates mitochondrial K ATP channels, limiting myocardial infarction. 119 In contrast, propofol protects against myocardial IRI mainly via its ROS scavenging properties, which enhances endogenous cardiac antioxidant capacity and ultimately attenuates myocardial IRI. 120 Opioids play an important role in mammalian hibernation. Endogenous and exogenous (e.g. remifentanil and morphine) opioid agonists reduce myocardial oxidative stress and Ca 2+ overload and attenuate myocardial IRI both in animal models and in patients undergoing cardiac surgery . [121] [122] [123] [124] Our most recent study shows that remifentanil preconditioning confers cardioprotection in rats, primarily via activation of JAK2/ STAT3 signalling, that can function independent of PI3K/Akt activation. 125 However, it should be noted that application of high doses of opioid receptor agonists such as morphine 126 and remifentanil 127 may cause significant increases in ROS production in the vascular endothelium and myocardium and subsequently impair vascular endothelial function and exacerbate myocardial ischaemia-reperfusion injury, although the doses of remifentanil required to do this are much higher than those used clinically.
Major randomized clinical trials of anaesthetic conditioning are listed in Table 1 which includes cardiac surgeries conducted under either on-pump or off-pump conditions. It should be mentioned that only the on-pump surgery provides typical ischaemia-reperfusion injury and that the duration of ischaemia time may be one of the determinants of the effectiveness of conditioning protection.
Similarity in mechanism and potential advantages of APC vs ischaemic conditioning
The concept of APC was evolved from IPC and IPo, and the mechanisms governing their cardioprotective effects are similar. APC confers cardioprotection mainly via the RISK and SAFE pathways (Fig. 4) . APC activates the RISK pathway via a G-proteincoupled cell surface receptor 128 and activates the SAFE pathway through the TNFα receptor, 8 129 which all inhibit IRI-induced mPTP opening and activate the opening of the K ATP channel, thereby protecting cardiomyocytes from IRI-induced cell death. However, unlike IPC and IPo, anaesthetic application during APC is to the whole body and it is possible, therefore, that APC may also exert protection to other organs and other types of cells rather than just cardiomyocytes. We have recently shown that sevoflurane pre-treatment protects against TNF-α-induced vascular endothelial dysfunction, through activation of the eNOS/NO pathway and inhibition of NF-κB. 130 Sevoflurane may also protect against liver injury in patients undergoing cardiac surgery. [131] [132] [133] [134] Exogenous opioids have also been shown to confer systemic multi-organ protection. Remifentanil pre-treatment ameliorated liver injury in rats subjected to hepatic ischaemia reperfusion 135 and attenuated intestinal ischaemia reperfusion injury in mice. 136 Compared with IPC and IPo, APC is more clinical feasible as anaesthetic agents are being used in surgery anyway. The beneficial effects of APC in a clinical setting was first demonstrated by Belhomme and colleagues 137 , who reported that isoflurane preconditioning (5 min isoflurane exposure followed by 10 min washout) reduced the release of cardiac troponin I (TnI) and creatine kinase MB (CKMB), markers of cardiac injury, in patients undergoing coronary artery bypass graft (CABG) surgery. Subsequently, the effects of APC in patients undergoing on-pump and off-pump CABG surgery have been examined with conflicting results. Exposure to isoflurane at 1-1.5 MAC end-tidal throughout surgery, reduced postoperative plasma TnI and CKMB release in patients undergoing CABG surgery with cardiopulmonary bypass. 138 While in patients undergoing off-pump CABG surgery, sevoflurane at 1 MAC provided optimal myocardial protection as increasing sevoflurane concentration to 1.5 MAC did not further attenuate myocardial injury and sevoflurane did not confer cardioprotection when being used at 0.75 MAC. 139 We also showed that treatment with propofol (120 mcg kg −1 min −1 for 10 min before the onset of CPB until 15 min after aortic unclamping and then decreased to 60 mcg kg −1 min −1 until the end of surgery) significantly attenuated cardiac injury in patients undergoing CABG, as compared with isoflurane or low dose propofol. 140 Continuous administration of 1 MAC desflurane induced cardioprotection in patients undergoing CABG surgery evidenced as reduced cardiac TnI release. 141 However, administration of isoflurane 1 MAC for 5 min followed by a 5 min washout before CPB, did not reduce troponin I concentrations in patients undergoing CABG with CPB. 142 Similarly, a double-blind trial showed that there was no difference among patients receiving propofol or sevoflurane during surgery in terms of postoperative recovery in the cardiac intensive care unit. 143 Thus, currently it is premature to draw a firm conclusion as to whether APC is beneficial in the clinical settings of CABG surgery, when patients are elderly with co-morbidities such as diabetes and hypertension.
A recent meta-analysis of 2578 patients where on pump and off pump patients were analysed separately, compared peak postoperative cardiac TnI between volatile and i.v. anaesthesia. Volatiles reduced postoperative peak serum cardiac TnI enzyme concentrations by ∼8% on-pump with no difference seen in off pump cardiac surgery. 144 An accompanying editorial stated 'So how much longer do we need to keep repeating that the use of a volatile anaesthetic regimen during on-pump coronary artery surgery is associated with a lower post-operative cardiac troponin release compared with an intravenous anaesthetic regimen?' and suggested that 'authors must stop designing and performing this type of study; ethical committees must stop approving such trials and editors must stop publishing over and over again data that simply confirm what is already known'. 145 However, all we can discern from such data is that although volatile anaesthetics do seem to reduce cTnI concentrations in I/R injury, the clinical significance of cTnI reduction is unclear (although likely to be good). I.V. anaesthesia in the above meta-analysis was not homogeneous, with midazolam and even etomidate included in that cohort, and, in our opinion, this does not mean that volatiles are preferable to propofol in patients with cardiovascular disease as both possess some, although different, cardioprotective properties. For example a large trial suggested that sevoflurane appears to be superior to propofol in patients with little or no ischaemic heart disease, such as non-coronary artery bypass graft (CABG) surgery and CABG surgery without severe preoperative ischaemia, whereas propofol seems superior in patients with severe ischaemia, and/or cardiovascular instability, possibly because myocardial ischaemia has already preconditioned the heart and propofol exerts it's protection differently. 146 Although experimental animal studies have consistently shown effective cardioprotection and have identified the specific cellular signalling involved, only a few studies have attempted to identify and confirm the specific cellular signalling of IPC, IPo, and APC in humans. More importantly, attempts to translate the findings regarding the mechanism and effectiveness of IPC, IPo, and APC from experimental animals into the clinical setting have largely failed. The reason for these failures might be: (1) many of the patients have comorbidities such as diabetes, aging, dyslipidemia, and hypertension which have been shown to influence the protective effects of IPC, IPo, and APC; (2) poor experimental design and no allowance for the use of concomitant medication such as anaesthetics. Some of the confounding factors such as age, diabetes and myocardial remodelling that may cause conflicting results in clinical trials have been discussed elsewhere 147 148 and summarized below.
Cardioprotection in diabetes and the impact of diabetes on anaesthetic cardioprotection
Higher rates of cardiovascular disease and mortality after AMI are observed in patients with diabetes. These patients are not only vulnerable to myocardial IRI but also not sensitive to cardioprotective strategies such as ischaemic conditioning and anaesthetic conditioning, that are effective in non-diabetic animal models of myocardial ischaemia/reperfusion or in non-diabetic patients undergoing CABG surgery. Clinically, diabetes is considered as an independent risk factor for cardiac injury during and after cardiac surgery. 149 Poorer recovery and higher mortality rates (two to against ischaemia reperfusion injury through the survivor activating factor enhancement (SAFE) and reperfusion injury salvage kinase (RISK) pathways, which, subsequently, through mitochondrial-dependent and non-mitochondrial-dependent (nuclear or other) signalling pathways, decrease mitochondrial permeability transition pore (mPTP) opening and increase mitochondrial KATP (Mito KATP) channel opening which attenuates ischaemia reperfusion injury.
four-fold higher than in non-diabetic subjects) after acute myocardial ischaemia/infarction (AMI) have also been reported. 150 Infarct size was 30-70% larger after reperfusion therapy (either thrombolytic therapy or percutaneous coronary intervention) in diabetic than in non-diabetic patients, 151 152 and worse short and long-term progression after AMI was observed. 153 154 Multiple factors have been proposed to contribute to the disparate outcomes regarding the susceptibility of diabetic hearts to myocardial IRI including: (1) the duration and the severity of the diabetic status; (2) the experimental protocols (e.g. type of animal species, severity of ischaemia and reperfusion); (3) the metabolic profiles of diabetic subjects at the time the experiment was conducted. Enhanced oxidative stress, which is mainly because of the burst production of ROS and/or depleted endogenous antioxidant system in diabetes, has been suggested as a major factor. 155 Increased oxidative stress has been shown to increase mPTP opening 156 and induce Ca 2+ overload, 157 factors that are attributable to myocardial IRI as discussed earlier. More importantly, enhanced oxidative stress may also impair endogenous cardioprotective signalling, which not only increases post-ischaemic myocardial injury in diabetic hearts but also diminishes or abolishes the protective effects of cardioprotective interventions such as ischaemic conditioning.
With a few exceptions, the cardioprotection of IPC, IPo, and APC has been shown to be compromised or even abolished in the hearts of diabetics. The effectiveness of sevoflurane postconditioning in reducing post-ischaemic myocardial infarct size and apoptosis in non-diabetic rats, was completely abrogated in streptozotocin-induced diabetic rats and diabetes blockade of sevoflurane postconditioning could not be restored by insulin, 8 although it could be restored by treatment with the antioxidant N-Acetylcysteine, which attenuated or restored diabetes induced reductions in cardiac p-STAT3 and adiponectin. 158 Defects in the RISK and SAFE pathways in diabetes have also been considered as a reason. 159 160 However, the exact role and the mechanism of reduced cardiac STAT3 activation in diabetes is not clear and needs further investigation, in order to facilitate the development of novel interventions to restore myocardial sensitivity to IPo in diabetes.
Major cardiovascular co-morbidities that may affect ischaemic or anaesthetic conditioning effects Ischaemic, anaesthetic preconditioning and postconditioning, trigger endogenous cardioprotective mechanisms that render the heart more resistant to lethal ischaemia-reperfusion injury. However, in addition to diabetes and senescence as aforementioned, certain major cardiovascular co-morbidities such as hyperlipidemia 161 162 cardiomyocyte hypertrophy, 163 hypertension, 164 165 and myocardial remodelling, 166 and many of their associated medications (e.g. β-blockers, glibenclamide, glicazide) may interfere with the mechanisms of conditioning cardioprotection, thereby limiting the efficacy of ischaemic or anaesthetic conditioning in clinical settings. The exact mechanisms by which these co-morbidities and medications interfere with conditioning cardioprotection are not well understood. Glibenclamide abolishes the protective effect of mitochondrial K ATP channel opening 167 and is one of the worst drugs in this regard. Statins may actually increase the effect of remote ischaemic conditioning 168 (interestingly, in this trial, smokers were more resistant to remote ischaemic conditioning). A recent analysis of patients undergoing elective CABG with/without remote ischaemic preconditioning found that β-blockers, statins, ACE inhibitors, ARBs and intraoperative nitroglycerine had no significant impact on remote ischaemic conditioninginduced cardioprotection. 109 Further comprehensive analysis of the cardioprotective genetic profile in normal, protected, and in comorbid conditions in the context of conditioning stimuli, may lead to identification of novel molecular targets for cardioprotection and facilitation of clinical translation.
Summary and future perspectives
Anaesthetic and ischaemia-induced myocardial protective effects are fascinating phenomena that have been extensively studied in various animal models with several mechanisms now elucidated. Clinically, beneficial effects, in terms of reduction in markers of cardiac injury, have also been demonstrated in patients undergoing heart surgery. Remote ischaemic conditioning, as a relatively simple and safe technique, may have particular clinical application (not only in protecting the heart but many other organs), however, many studies have been hampered by small sample sizes and lack of hard and more long-term clinical outcome data, with many relying on surrogate markers of cardiac injury. Certain patients that are particularly vulnerable to vascular complications (e.g. those with diabetes, hypertension and senescence), are particularly resistant to cardiac conditioning of all forms and this may be further complicated by adjuvant pharmacotherapy. Despite some 'proof of concept', large randomized clinical trials are still needed to determine whether this is just a healthy heart phenomenon or whether it's something that we can routinely use to protect our increasingly high-risk patients undergoing cardiac and vascular surgery.
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